BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1564 related articles for article (PubMed ID: 32474885)

  • 1. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
    Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S
    Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
    Alunno A; Carubbi F; Rodríguez-Carrio J
    RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
    Misra DP; Agarwal V; Gasparyan AY; Zimba O
    Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
    Soy M; Atagündüz P; Atagündüz I; Sucak GT
    Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.
    McGonagle D; Sharif K; O'Regan A; Bridgewood C
    Autoimmun Rev; 2020 Jun; 19(6):102537. PubMed ID: 32251717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
    Opoka-Winiarska V; Grywalska E; Roliński J
    BMC Med; 2020 Jul; 18(1):214. PubMed ID: 32664932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
    Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
    J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S; Sun W; Li M; Dong L
    Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine storm in severe COVID-19 pneumonia.
    Gürsoy B; Sürmeli CD; Alkan M; Satıcı C; Altunok ES; Kamat S; Demirok B; Demirkol MA; Börü A
    J Med Virol; 2021 Sep; 93(9):5474-5480. PubMed ID: 33963559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaco-Immunomodulatory Therapy in COVID-19.
    Rizk JG; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Forthal DN
    Drugs; 2020 Sep; 80(13):1267-1292. PubMed ID: 32696108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
    Ye Q; Wang B; Mao J
    J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tackling the cytokine storm in COVID-19, challenges and hopes.
    Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
    Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients.
    Lorenz G; Moog P; Bachmann Q; La Rosée P; Schneider H; Schlegl M; Spinner C; Heemann U; Schmid RM; Algül H; Lahmer T; Huber W; Schmaderer C
    Sci Rep; 2020 Oct; 10(1):18277. PubMed ID: 33106497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
    Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
    Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
    Wang J; Jiang M; Chen X; Montaner LJ
    J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
    Dalamaga M; Karampela I; Mantzoros CS
    Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
    Liu JM; Chi J
    Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.